113 related articles for article (PubMed ID: 7645963)
1. RS-33295-198: a novel, potent modulator of P-glycoprotein-mediated multidrug resistance.
Slate DL; Bruno NA; Casey SM; Zutshi N; Garvin LJ; Wu H; Pfister JR
Anticancer Res; 1995; 15(3):811-4. PubMed ID: 7645963
[TBL] [Abstract][Full Text] [Related]
2. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
Dantzig AH; Shepard RL; Cao J; Law KL; Ehlhardt WJ; Baughman TM; Bumol TF; Starling JJ
Cancer Res; 1996 Sep; 56(18):4171-9. PubMed ID: 8797588
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
Nakanishi O; Baba M; Saito A; Yamashita T; Sato W; Abe H; Fukazawa N; Suzuki T; Sato S; Naito M; Tsuruo T
Oncol Res; 1997; 9(2):61-9. PubMed ID: 9167187
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
5. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
6. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
8. New purines and purine analogs as modulators of multidrug resistance.
Dhainaut A; Regnier G; Tizot A; Pierre A; Leonce S; Guilbaud N; Kraus-Berthier L; Atassi G
J Med Chem; 1996 Sep; 39(20):4099-108. PubMed ID: 8831775
[TBL] [Abstract][Full Text] [Related]
9. Retroviral coexpression of two different types of drug resistance genes to protect normal cells from combination chemotherapy.
Suzuki M; Sugimoto Y; Tsukahara S; Okochi E; Gottesman MM; Tsuruo T
Clin Cancer Res; 1997 Jun; 3(6):947-54. PubMed ID: 9815770
[TBL] [Abstract][Full Text] [Related]
10. Reversal of multidrug resistance by a novel quinoline derivative, MS-209.
Sato W; Fukazawa N; Nakanishi O; Baba M; Suzuki T; Yano O; Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1995; 35(4):271-7. PubMed ID: 7828268
[TBL] [Abstract][Full Text] [Related]
11. MDL 201,307: a novel benzothiazepine modulator of multiple drug resistance.
Newman RA; Fan D; Munson HR; Martin LA; Ahmed NK
J Exp Ther Oncol; 1996 Mar; 1(2):109-18. PubMed ID: 9414394
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
Hyafil F; Vergely C; Du Vignaud P; Grand-Perret T
Cancer Res; 1993 Oct; 53(19):4595-602. PubMed ID: 8402633
[TBL] [Abstract][Full Text] [Related]
14. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.
Gao L; Chen L; Fei XH; Qiu HY; Zhou H; Wang JM
Chin Med J (Engl); 2006 Jun; 119(11):911-8. PubMed ID: 16780770
[TBL] [Abstract][Full Text] [Related]
15. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
[TBL] [Abstract][Full Text] [Related]
16. Selective enhancement of vincristine cytotoxicity in multidrug-resistant tumor cells by dilantin (phenytoin).
Ganapathi R; Hercbergs A; Grabowski D; Ford J
Cancer Res; 1993 Jul; 53(14):3262-5. PubMed ID: 8100737
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines.
Johnstone SA; Gelmon K; Mayer LD; Hancock RE; Bally MB
Anticancer Drug Des; 2000 Apr; 15(2):151-60. PubMed ID: 10901303
[TBL] [Abstract][Full Text] [Related]
18. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
19. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells.
Tsuruo T; Iida H; Kitatani Y; Yokota K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Oct; 44(10):4303-7. PubMed ID: 6467192
[TBL] [Abstract][Full Text] [Related]
20. Novel multidrug resistance reversal agents.
Berger D; Citarella R; Dutia M; Greenberger L; Hallett W; Paul R; Powell D
J Med Chem; 1999 Jun; 42(12):2145-61. PubMed ID: 10377220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
